BioSpace News Archive

Clinicians report spending more than twice the amount of time they would like to on supply chain-related tasks, and as a result have less time with patients and increased stress levels, according to the fourth annual Cardinal Health Hospital Supply Chain Survey.

BerGenBio ASA selective AXL kinase inhibitors for multiple cancer indications, announces its results for the first quarter 2019.

The lasmiditan Phase 3 program encompassed more than 4,000 patients and 20,000 migraine attacks

Hill-Rom Holdings, Inc., announced that its board of directors declared a fiscal 2019 third quarter dividend of $0.21 per share payable on June 28, 2019, to shareholders of record as of the close of business on June 21, 2019.

Clarkston Consulting announced that it will participate at SAPPHIRE NOW® and ASUG Annual Conference being held May 7-9 in Orlando, Florida in booth #1234.

Aquestive Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2019 and provided an update on recent developments in its business.

Exhibits Collaboration Portal and Three Scientific Posters

Protagonist Therapeutics, Inc. announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc. for the co-development and commercialization of PTG-200, Protagonist’s first-in-class, oral peptide IL-23 receptor antagonist, for all indications including inflammatory bowel disease (IBD).

Protagonist Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2019.

Test It Back campaign encourages patients newly diagnosed with non-small cell lung cancer to ensure they receive a full diagnosis and the treatment that is right for them